During the last session, Legend Biotech Corp ADR (NASDAQ:LEGN)’s traded shares were 0.9 million, with the beta value of the company hitting 0.11. At the end of the trading day, the stock’s price was $45.30, reflecting an intraday gain of 1.98% or $0.88. The 52-week high for the LEGN share is $77.32, that puts it down -70.68 from that peak though still a striking 2.74% gain since the share price plummeted to a 52-week low of $44.06. The company’s market capitalization is $8.24B, and the average trade volume was 986.11K shares over the past three months.
Legend Biotech Corp ADR (NASDAQ:LEGN) trade information
Legend Biotech Corp ADR (LEGN) registered a 1.98% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 1.98% in intraday trading to $45.30, hitting a weekly high. The stock’s 5-day price performance is -1.93%, and it has moved by -20.43% in 30 days. Based on these gigs, the overall price performance for the year is -33.33%.
Legend Biotech Corp ADR (LEGN) estimates and forecasts
Statistics show that Legend Biotech Corp ADR has underperformed its competitors in share price, compared to the industry in which it operates. Legend Biotech Corp ADR (LEGN) shares have gone down -29.20% during the last six months, with a year-to-date growth rate less than the industry average at 8.16% against 12.90. In the rating firms’ projections, revenue will increase 103.70% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 153.36M as predicted by 11 analyst(s). Meanwhile, a consensus of 11 analyst(s) estimates revenue growth to 127.55M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 36.34M and 73.33M respectively. In this case, analysts expect current quarter sales to grow by 322.10% and then jump by 73.90% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -168.48%. While earnings are projected to return 22.29% in 2024.
LEGN Dividends
Legend Biotech Corp ADR is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
